ProMIS Neurosciences is a biotechnology company based in Toronto, Ontario, and Cambridge, Massachusetts. They are dedicated to discovering and developing therapeutic antibodies that target toxic oligomers associated with neurodegenerative diseases and other misfolded protein diseases. Using their proprietary target discovery engine, they can identify Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that contribute to the progression of diseases like Alzheimer’s, ALS, and Parkinson’s.

What sets ProMIS Neurosciences apart is their innovative approach, which combines computational modeling and scientific research by Dr. Neil Cashman to generate highly selective antibodies. This approach offers potential benefits such as improved efficacy, tolerability, and safety.

ProMIS Neurosciences is actively building a portfolio of therapeutic antibodies, vaccines, and diagnostics to combat these diseases and bring selective antibody therapies closer to patients. Led by a team of experienced leaders in medicine and advised by renowned scientists, they are at the forefront of groundbreaking science in the field of neurodegenerative diseases